Potential Link Between Ozempic and a Rare Eye Disease
The Danish Medicines Agency has requested the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) to review findings from two Danish studies suggesting a link between Novo Nordisk’s diabetes drug, Ozempic, and a rare vision-threatening eye disease.
The studies conducted by researchers at the University of Southern Denmark (SDU) indicate that Ozempic more than doubles the risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare ischemic eye condition, in individuals with type 2 diabetes.
These findings add to concerns raised by a U.S. study published earlier this year.
End of Message
Feel free to share this content with attribution to The World of Health and Medicine.
